Multaq Legal News Articles & Interviews

Washington, DC It has been little over a year since a clinical trial exploring the benefits of Multaq and Multaq side effects was halted due to concerns over cardiac events. At the time, the Los Angeles Times (7/7/11) noted Multaq manufacturer Sanofi Aventis had referenced a "significant increase in cardiovascular events" amongst participants of the PALLUS study.

Houston, TX When it comes to determining whether the risks of Multaq side effects are worth the benefits, patients might consider the Multaq warning issued by the US Food and Drug Administration. They might also take into account the risk of Multaq liver damage and Multaq contraindications. But because the drug is used to treat a heart condition, they might think that all those risks are outweighed by the benefits.

Los Angeles, CA Citing concerns about the risk of Multaq side effects, scientists have warned that Multaq not be used as a first-line treatment for certain conditions. Although Multaq warnings have been issued by the US Food and Drug Administration (FDA) and international health agencies, the atrial fibrillation drug is still available on the market. In December 2011, however, the FDA announced that clinical trials suggested an increased risk of Multaq health problems.

Louisville, KY Any doctor will tell you that every drug has side effects—including heart drug Multaq. In fact, Multaq side effects are compelling. But even though the US Food and Drug Administration (FDA) has Multaq under a microscope and issued a cautionary statement about dronedarone (Multaq) as recently as February, the agency is resisting any effort to request a Multaq recall.

Boston, MA When patients deal with serious drug side effects, such as Multaq side effects, they often assume that, despite the side effects, they are taking the best medication available, making the side effects a necessary evil. But for people suffering from Multaq problems, especially in the face of recent Multaq warnings, news that Multaq may not have been the best drug is probably surprising.

Washington, DC The concern over Multaq side effects has, not surprisingly, made it to the pages of Cardiology News (2/12). Ever since the US Food and Drug Administration (FDA) issued a health alert last December with regard to dronedarone (Multaq) and the risk to patients with permanent atrial fibrillation (AF), the cardiology world is proceeding with renewed caution over the Multaq portfolio.

Spokane, WA Patients concerned about the risk of Multaq side effects can probably be forgiven, since their concern comes on the heals of an FDA Multaq warning. The warning, issued in December 2011, warned about the risk of Multaq heart problems—a concern because Multaq is approved to treat atrial flutter. But the FDA's January Multaq warning was not the first about the drug in 2011.

Washington, DC The annual observance of American Heart Month is a time for superlatives and overtures about heart health. Diet, exercise, excessive weight and smoking are the missives coming to the fore that can contribute to a healthy heart, or a heart attack.

Washington, DC 'Twas the week before Christmas, and…well, you know how the rhyme goes. In this case the French drugmakers at Sanofi were not stirring, waiting for the US Food and Drug Administration (FDA) to articulate its position on Multaq side effects—and with hopes that a reprieve, soon would be there…

Washington, DC The US Food and Drug Administration (FDA) announced in July 2011 that it was reviewing possible Multaq side effects after data from a study indicated an increased risk of Multaq heart problems. The FDA's announcement came following information that a Multaq atrial fibrillation study was stopped early due to serious dronedarone side effects.